StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX - Get Free Report) in a research note issued to investors on Tuesday. The firm set a "sell" rating on the stock.

Separately, Benchmark reiterated a "hold" rating on shares of VolitionRx in a research note on Friday, August 16th.

VolitionRx Stock Up 5.2 %

Shares of VNRX traded up $0.04 during mid-day trading on Tuesday, reaching $0.75. The company's stock had a trading volume of 158,637 shares, compared to its average volume of 161,519. The business has a fifty day moving average of $0.68 and a 200 day moving average of $0.68. The company has a market cap of $68.89 million, a price-to-earnings ratio of -1.79 and a beta of 1.10. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.23.

VolitionRx (NYSE:VNRX - Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.01. The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.34 million. On average, analysts predict that VolitionRx will post -0.31 earnings per share for the current year.

Insider Transactions at VolitionRx

In related news, Director Guy Archibald Innes purchased 150,000 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was acquired at an average price of $0.67 per share, with a total value of $100,500.00. Following the completion of the acquisition, the director now directly owns 406,683 shares in the company, valued at approximately $272,477.61. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 12.80% of the company's stock.

Institutional Trading of VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC boosted its stake in VolitionRx Limited (NYSE:VNRX - Free Report) by 78.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,959 shares of the company's stock after acquiring an additional 20,249 shares during the quarter. Ground Swell Capital LLC's holdings in VolitionRx were worth $28,000 as of its most recent SEC filing. 8.09% of the stock is owned by institutional investors and hedge funds.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.